Chinese trade negotiators suddenly canceled a visit to meet U.S. farmers after they wrapped up trade talks in Washington this week.Marketsread more
President Trump also said he is "not looking for a partial deal" with Beijing, moving away from his suggestion last week that he would consider an "interim deal."Politicsread more
For investors taking a breather from the chaos in August, buckle up as the market is about go crazy again, Goldman Sachs warned.Marketsread more
Canadian trade union Unifor said roughly 4,500 of its members have been temporarily laid off because of the GM strike so far.Autosread more
With "tariff man" President Trump waging a tariff war and Democratic candidates pushing against big international deals, free trade has become politically homeless, writes...2020 Electionsread more
Since the Cambridge Analytica scandal in March 2018, Facebook has suspended tens of thousands of apps stemming from an investigation into its developer ecosystem.Technologyread more
The former top aide of retired United Auto Workers Vice President Joe Ashton, a former member of the GM's board, was charged Friday with conspiracy to commit wire fraud and...Autosread more
Stocks fell to their lows of the day on Friday on news that Chinese trade officials are cutting short their visit to the U.S.US Marketsread more
The wearables company has retained advisors to consider exploring a sale of the business.Technologyread more
Roku shares have more than quadrupled this year, but the stock has had some rocky days of late as more players jump into streaming.Technologyread more
"I really want to encourage competition because I think competition creates innovation, and when you create innovation everyone wins," Humana CEO Bruce Broussard says.Health and Scienceread more
Shares of drug distributors fell Tuesday after a report said McKesson, Cardinal Health and AmerisourceBergen have proposed paying $10 billion to settle claims they helped to fuel the U.S. opioid epidemic.
The companies made the verbal proposal as part of talks with a group of state attorneys general, according to Bloomberg, citing three people familiar with the offer. The National Association of Attorneys General, which is the handling talks on behalf of several states, countered with a demand for $45 billion to cover costs from the crisis, the report said.
Whether the drug distributors and attorneys general can agree to a deal remains uncertain, according to the report.
Shares of the drug distributors, which deliver the majority of prescription medications to U.S. pharmacies, fell Tuesday. McKesson closed down 3.9%, Cardinal Health dropped 5.8% and AmerisourceBergen shed 5.2%.
Mallinckrodt, the largest manufacturer of oxycodone and hydrocodone pain pills, closed down 12%. The company said earlier Tuesday it would suspend its plans to spin out its generics unit, which includes opioids. Mallinckrodt previously had said the spinout would separate its main business from any potential liabilities from opioid litigation. Company executives Tuesday cited "uncertainty around that opioid litigation" leading to its "decision to suspend, for now, the spin plans."
The report comes as some 1,600 cases against OxyContin maker Purdue Pharma and other opioid manufacturers are being consolidated and transferred to a judge in the Northern District of Ohio. The companies have asked for a delay for the trial set in October.
Lawyers have compared the opioid litigation to the tobacco master settlement agreement in the mid- and late-1990s where the nation's four largest tobacco companies reached a group settlement with 46 state attorneys general.
In a statement to CNBC, McKesson said, "We regularly engage with the state attorneys general, but the company has made no settlement offers."
Cardinal Health and AmerisourceBergen declined to comment.
The opioid epidemic is a major issue for the federal government, which has vowed to crack down on illicit use. More than 130 people in the U.S. die every day from opioid overdoses, with about 47,000 people dying in 2017, according to data from the U.S. Centers for Disease Control and Prevention.
In March, Purdue, and its owners, the Sackler family, agreed to pay $270 million to Oklahoma to settle a lawsuit accusing the drugmaker of ruthlessly marketing and misleading the public about OxyContin. As a part of that agreement, Purdue agreed to contribute $102.5 million to fund the creation of a National Center for Addiction Studies at Oklahoma State University.
— CNBC's Meg Tirrell contributed to this report.